Memory Loss & Cognitive Care

Some forgetfulness with age is normal — misplacing keys occasionally, briefly forgetting a name, or needing more time to learn something new. Mild cognitive impairment (MCI) is a noticeable, persistent change in memory or thinking that goes beyond normal aging but does not yet interfere significantly with independent daily life. Dementia is when cognitive change is severe enough to interfere with daily activities — paying bills, managing medications, cooking, driving, working. MCI does not always progress to dementia, but it does require evaluation.

Alzheimer's disease is the most common, accounting for about 60–70% of dementia cases in older adults. Other causes include vascular dementia (from strokes or chronic small-vessel disease), Lewy body dementia (associated with visual hallucinations, REM sleep behavior disorder, and parkinsonism), frontotemporal dementia (often presenting with personality or language changes), and mixed dementias. Less common but reversible causes include B12 deficiency, hypothyroidism, normal-pressure hydrocephalus, and depression — which is why a careful evaluation matters.

Yes — and this is one of the main reasons to be evaluated. Reversible or partially reversible causes include depression (sometimes called 'pseudodementia'), thyroid dysfunction, B12 deficiency, severe sleep apnea, medication side effects (especially anticholinergics, sedatives, and chronic opioids), excessive alcohol use, normal-pressure hydrocephalus, and chronic subdural hematoma. A complete workup screens for all of these.

A typical evaluation includes a detailed history (often with a family member present), a neurological examination, brief in-office cognitive testing (such as the MoCA — Montreal Cognitive Assessment), blood work (thyroid, B12, metabolic panel), and brain MRI to look for strokes, atrophy patterns, hydrocephalus, or other structural causes. In selected cases, more detailed neuropsychological testing, PET imaging, blood-based amyloid biomarkers, or lumbar puncture for cerebrospinal fluid biomarkers may be appropriate.

The Montreal Cognitive Assessment (MoCA) is a 30-point screening tool that takes about 10 minutes to administer. It tests memory, attention, language, executive function, visuospatial skills, and orientation. A score of 26 or above is generally considered normal; 18–25 suggests mild impairment; below 18 suggests moderate to severe impairment. It is a screening tool, not a diagnosis — the clinical context, education level, and history all matter.

Yes. Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine are FDA-approved symptomatic treatments that can modestly improve or stabilize cognition for a period of time. Newer disease-modifying anti-amyloid antibodies (lecanemab, donanemab) are FDA-approved for early Alzheimer's disease in carefully selected patients with confirmed amyloid pathology, and require regular MRI monitoring for side effects. Optimizing cardiovascular risk factors, sleep, and depression also makes a meaningful difference.

The most helpful steps are practical: simplify medication regimens (use weekly pillboxes or automated dispensers), set up automatic bill pay, consider a single bank account with limited withdrawal capacity, plan for safe driving (an evaluation may help), label items at home, install grab bars and remove fall hazards, and join a caregiver support group. Long-term planning around finances, advance directives, and power of attorney is best done early when the person can participate. The Alzheimer's Association (alz.org, helpline 1-800-272-3900) is an excellent local resource.

Reassuring patterns include occasional forgetfulness that you eventually remember, briefly losing your train of thought, or needing more time to learn something new. Concerning patterns include repeating the same question several times within a short period, getting lost while driving in familiar areas, missing or duplicating bill payments, becoming confused about time or place, withdrawing from previously enjoyed activities, or noticeable personality changes. When in doubt, an evaluation is reasonable — early diagnosis often opens more options.

Yes. While most dementia is age-related, conditions such as early-onset Alzheimer's disease, frontotemporal dementia, autoimmune encephalitis, multiple sclerosis, and post-concussion syndrome can affect cognition in younger adults. Persistent cognitive changes at any age deserve evaluation, especially when they affect work or daily function.